Home At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
 

Keywords :   


At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted

2014-12-13 11:24:24| Biotech - Topix.net

Myriad Genetics, Inc. has announced results from a new study that demonstrated the ability of the myRisk Hereditary Cancer test to detect 105 percent more mutations in cancer causing genes than conventional BRCA testing alone. The Company also presented two key studies in triple negative breast cancer that show the myChoice HRD test accurately predicted response to platinum-based therapy in patients with early-stage TNBC and that the BRACAnalysis molecular diagnostic test significantly predicted response to platinum-based drugs in patients with metastatic TNBC.

Tags: san studies antonio cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
22.11SHIMANO BT Master 11AP)
22.11
22.11
22.11GOLDWIN
22.11Qi10 TOUR 5W WF
22.11
22.11GX HR
22.11 GEORGIA
More »